Japan Compounding Pharmacies Market size was valued at USD 142.60 million in 2018 and increased to USD 221.90 million in 2024. The market is anticipated to reach USD 403.45 million by 2032, growing at a CAGR of 7.23% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Japan Compounding Pharmacies Market Size 2024
USD 221.90 Million
Japan Compounding Pharmacies Market, CAGR
7.23%
Japan Compounding Pharmacies Market Size 2032
USD 403.45 Million
The Japan Compounding Pharmacies Market is led by key players such as Nichi-Iko Pharmaceutical Co. Ltd., Towa Pharmaceutical Co., Ltd., Sato Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Limited. These companies are focusing on expanding their presence through product portfolio diversification, technological advancements in sterile and non-sterile compounding, and strategic collaborations with hospitals and clinics. The market emphasizes patient-centric therapies, including pediatric, geriatric, and chronic care formulations, which drive competitive dynamics. Among regions, the Kanto region emerges as the leader, accounting for 35% of the market share, supported by high population density, advanced healthcare infrastructure, and the presence of major specialty clinics. Continuous investment in personalized medications, coupled with regulatory compliance and adoption of precision compounding technologies, positions these top players and the Kanto region at the forefront of Japan’s evolving compounding pharmacy landscape.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Japan Compounding Pharmacies Market was valued at USD 221.90 Million in 2024 and is projected to reach USD 403.45 Million by 2032, growing at a CAGR of 7.23%. The market is segmented by product type, pharmacy type, and sterility, with oral medications holding a 38% share and 503A pharmacies dominating with 65%.
Rising demand for personalized medicine and patient-specific formulations is driving market growth, supported by increasing prevalence of chronic and rare diseases across Japan.
Trends indicate growing adoption of biologics and injectable therapies, along with expanding opportunities in pediatric and geriatric care, boosting the need for customized dosage forms.
Competitive dynamics are shaped by leading players such as Nichi-Iko Pharmaceutical, Towa Pharmaceutical, and Sato Pharmaceutical, who focus on innovation, regulatory compliance, and expansion of sterile and non-sterile compounding capabilities.
Regionally, Kanto leads with a 35% market share, followed by Kansai at 22%, Chubu at 18%, Kyushu at 12%, Tohoku at 8%, and Hokkaido at 5%, reflecting strong healthcare infrastructure and concentration of specialty clinics.
Market Segmentation Analysis:
By Product Type:
Oral medications dominate the product type segment, accounting for approximately 38% of the Japan Compounding Pharmacies Market. This sub-segment benefits from the rising demand for customized doses and patient-specific formulations, particularly for chronic conditions such as cardiovascular diseases and diabetes. Injectable medications follow closely with a 32% share, driven by the growing need for targeted therapies and biologics requiring precision compounding. Topical preparations, nasal formulations, and others collectively contribute around 30%, supported by increasing applications in dermatology, pain management, and respiratory treatments. Personalized care and improved patient compliance continue to propel growth across all product types.
For instance, in Japan, loxoprofen and celecoxib are among the most frequently prescribed oral analgesics, often tailored to patient needs, with careful adherence to approved dosing regimens to minimize adverse effects.
By Pharmacy Type:
503A pharmacies hold a dominant position in Japan, representing nearly 65% of the market share. These traditional compounding pharmacies cater to individual prescriptions and benefit from streamlined regulatory frameworks, ensuring rapid formulation for patient-specific needs. The growth is further fueled by increasing awareness of personalized medicine and rising prevalence of chronic diseases. 503B pharmacies, while smaller with a 35% share, are expanding due to their ability to provide large-scale sterile compounding and supply to hospitals, clinics, and specialty healthcare facilities, meeting growing demand for high-quality compounded medications across institutional settings.
For instance, 503B pharmacies, such as those operated by companies like Wedgewood Pharmacy or PharMEDium, are expanding their large-scale sterile compounding capabilities, producing bulk medications such as infused fluids or high-volume sterile solutions for hospitals, meeting the increased demand for institutional supply with adherence to FDA cGMP standards.
By Sterility:
Sterile compounding emerges as the leading sub-segment with a 58% market share, driven by high demand for injectable, ophthalmic, and intravenous formulations requiring stringent safety and quality standards. Growth is supported by the rising prevalence of chronic and critical conditions, including oncology and rare diseases, which require precise sterile preparations. Non-sterile compounding, holding a 42% share, caters to oral, topical, and other non-injection formulations, benefiting from patient preference for personalized dosage forms and flavors. Continuous regulatory emphasis on quality and patient safety fuels expansion in both sterile and non-sterile compounding services.
Key Growth Drivers
Rising Demand for Personalized Medicine
The growing emphasis on personalized medicine is a significant growth driver in Japan’s compounding pharmacies market. Patients increasingly seek customized formulations tailored to individual health profiles, particularly for chronic conditions, hormone replacement therapy, and pediatric or geriatric care. Compounding pharmacies provide precise dosages, alternative flavors, and specialized delivery methods that improve compliance and patient outcomes. The shift toward patient-centric healthcare and the expansion of precision therapies continue to drive demand for individualized medications, positioning compounding pharmacies as essential contributors to Japan’s evolving pharmaceutical landscape.
For instance, Bushu Pharma is a veteran contract manufacturing organization (CMO) providing custom pharmaceutical manufacturing services, including development and production of tailored drug formulations.
Increasing Prevalence of Chronic and Rare Diseases
The rising incidence of chronic illnesses and rare diseases fuels market growth in Japan. Conditions such as diabetes, cardiovascular disorders, cancer, and autoimmune diseases require specialized drug formulations often unavailable in standard commercial products. Compounding pharmacies address these unmet needs by producing patient-specific dosages and unique therapeutic combinations. Hospitals, clinics, and home-care settings increasingly rely on these tailored medications to enhance treatment efficacy, reduce side effects, and support complex therapies, strengthening the market’s role in improving clinical outcomes across diverse patient populations.
For instance, Takeda Pharmaceutical recently received approval for TAKHZYRO® (lanadelumab), a subcutaneous injection drug for hereditary angioedema, with 41.7% of patients in a Japan-specific study not developing attacks during treatment.
Regulatory Support and Technological Advancements
Supportive regulations and technological innovations contribute to the market’s expansion. Japan has established frameworks that enable safe and efficient compounding practices, particularly for sterile preparations. Advanced automation, precision compounding equipment, and quality monitoring systems enhance safety, reduce errors, and improve production efficiency. These developments empower pharmacies to scale operations while maintaining compliance, allowing wider adoption of compounded medications in hospitals and specialty clinics. Continuous investment in research and development further supports innovation, ensuring the delivery of high-quality, patient-specific pharmaceutical solutions.
Key Trends & Opportunities
Trend Toward Biologics and Injectable Therapies
The Japan compounding pharmacies market is witnessing a trend toward biologics and injectable therapies. Increasing adoption of monoclonal antibodies, hormone therapies, and targeted injectable treatments drives demand for sterile compounding capabilities. This trend reflects the broader shift in healthcare toward advanced therapies that require precision handling and customized dosing. Compounding pharmacies capable of producing high-quality injectable biologics are gaining a competitive advantage, meeting hospital and clinical requirements while supporting patient-centric care models in oncology, endocrinology, and immunology segments.
For instance, Kyowa Hakko Kirin’s POTELIGEO® (mogamulizumab) injection is a humanized monoclonal antibody approved in Japan to treat relapsed or refractory adult T-cell leukemia-lymphoma, demonstrating the role of advanced monoclonal antibody therapies in compounding.
Opportunity in Geriatric and Pediatric Care
Growing geriatric and pediatric populations present a significant opportunity for compounding pharmacies in Japan. Elderly patients often require tailored dosages and alternative formulations to manage multiple chronic conditions, while pediatric patients benefit from liquid, flavored, or easily ingestible medications. The rising focus on improving adherence, safety, and therapeutic outcomes in these demographic groups creates demand for specialized compounding services. Pharmacies that innovate in age-appropriate formulations and delivery systems can capture market share while addressing critical gaps in conventional pharmaceutical offerings.
For instance, the Suzuken Group has developed community pharmacies with sterile drug preparation rooms and pharmacists providing home visits and medication guidance, specifically addressing complex medication needs for elderly patients receiving home care.
Key Challenges
Regulatory Compliance and Quality Control Challenges
strict regulatory compliance and maintaining high-quality standards poses challenges in Japan’s compounding pharmacies market. Sterile compounding and customized formulations require rigorous monitoring, testing, and documentation to meet safety regulations. Non-compliance risks recalls, penalties, and reputational damage, while complex procedures increase operational costs. Balancing efficiency, accuracy, and adherence to standards demands investment in skilled personnel, equipment, and training, making regulatory compliance a critical hurdle that companies must continuously address to sustain growth and patient trust.
Limited Awareness and Adoption Among Patients
Limited awareness and adoption of compounded medications among certain patient groups restrict market expansion. Many patients and caregivers remain unfamiliar with the benefits of personalized formulations or perceive compounded drugs as less accessible compared to standard commercial products. This lack of awareness can slow uptake in outpatient and home-care settings, despite clinical advantages. Compounding pharmacies must invest in education, marketing, and collaboration with healthcare providers to increase visibility, demonstrate therapeutic value, and encourage broader adoption of customized medication solutions across diverse patient demographics.
Regional Analysis
Kanto Region
The Kanto region leads the Japan Compounding Pharmacies Market with a 35% market share, driven by high population density, advanced healthcare infrastructure, and the presence of major hospitals and specialty clinics. Rising demand for personalized medications, particularly in Tokyo and Yokohama, fuels growth across oral, injectable, and topical formulations. The region also benefits from strong regulatory compliance and advanced compounding facilities, enabling pharmacies to efficiently cater to chronic, geriatric, and pediatric patient populations. Continuous investments in sterile and non-sterile compounding, coupled with increased awareness of tailored therapies, reinforce Kanto’s dominant position in the market.
Kansai Region
The Kansai region accounts for a 22% share of Japan’s compounding pharmacies market. Urban centers such as Osaka, Kyoto, and Kobe serve as hubs for healthcare innovation and specialty pharmaceutical services. Growing prevalence of chronic diseases and rising geriatric population are driving demand for customized oral and injectable medications. Kansai’s well-established network of 503A and 503B pharmacies facilitates distribution of sterile and non-sterile formulations. Expansion of hospital collaborations and technological adoption in compounding practices further strengthens the market, making Kansai a key region for both patient-specific therapies and advanced pharmacy operations.
Chubu Region
Chubu holds an 18% market share in Japan’s compounding pharmacies market, benefiting from a balanced mix of urban and semi-urban healthcare facilities. The demand for personalized medications, especially in Nagoya and surrounding cities, supports growth in oral, injectable, and topical formulations. Chubu’s pharmacies focus on both adult and pediatric care, leveraging technological advancements in compounding to ensure precision and safety. Expansion in sterile compounding services, coupled with increased awareness of customized therapies, contributes to the region’s steady market development. The presence of several mid-sized compounding pharmacies strengthens Chubu’s role as a key regional contributor.
Kyushu Region
The Kyushu region contributes 12% to Japan’s compounding pharmacies market, supported by growing healthcare infrastructure in cities such as Fukuoka and Kumamoto. Rising awareness of personalized medications among chronic and pediatric patients drives demand for both sterile and non-sterile formulations. Local pharmacies are increasingly adopting advanced compounding technologies to improve accuracy and efficiency in customized therapies. The region’s strategic initiatives, including collaborations with hospitals and clinics, further enhance access to specialized medications. Kyushu’s growth is fueled by increasing patient focus on tailored treatments and the expansion of 503A and 503B compounding pharmacies.
Tohoku Region
The Tohoku region holds an 8% market share in the Japan Compounding Pharmacies Market, driven by expanding healthcare services in Sendai and surrounding cities. The region shows increasing adoption of personalized oral and injectable medications to manage chronic conditions and geriatric care. While smaller in scale than Kanto or Kansai, Tohoku’s pharmacies are investing in sterile compounding capabilities to meet hospital and specialty clinic demands. Rising awareness among patients and healthcare providers supports gradual market expansion, with regional players focusing on quality, safety, and accessibility of compounded therapies across both adult and pediatric populations.
Hokkaido Region
Hokkaido represents 5% of the Japan compounding pharmacies market, with growth supported by urban centers such as Sapporo and Asahikawa. Demand for patient-specific medications, particularly oral and topical formulations, drives market activity. The region’s pharmacies focus on improving compliance and therapeutic outcomes for chronic and pediatric patients through specialized formulations. Despite geographical challenges, technological adoption and collaboration with hospitals and clinics enable Hokkaido’s compounding pharmacies to deliver sterile and non-sterile medications efficiently. Increasing awareness of the benefits of personalized therapies among patients and caregivers is gradually boosting market penetration in this northern region.
Market Segmentations:
By Product Type
Oral Medications
Injectable Medications
Topical Preparations
Nasal Formulations
Others
By Pharmacy Type
503A Pharmacies
503B Pharmacie
By Sterility
Sterile Compounding
Non-Sterile Compounding
By Therapeutic Area
Hormone Replacement Therapy
Pain Management
Specialty Drugs
Dermatology
Nutritional Supplements
Others
By Patient Demographics
Adults
Pediatrics
Geriatrics
Others
By Region
Kanto
Kansai
Chubu
Kyushu
Thoku
Hokaido
Competitive Landscape
The competitive landscape of the Japan Compounding Pharmacies Market includes key players such as Nichi-Iko Pharmaceutical Co. Ltd., Towa Pharmaceutical Co., Ltd., Sato Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Limited. These companies are focusing on expanding their presence through strategic partnerships, technological advancements, and product portfolio diversification to address the growing demand for personalized medications. Market players are investing in sterile and non-sterile compounding capabilities, enhancing quality control, and adopting automation to improve efficiency. Additionally, the emphasis on patient-centric therapies, such as pediatric, geriatric, and chronic care formulations, is shaping competition. Smaller regional pharmacies are also leveraging niche segments and specialized services to gain market share. Overall, competitive dynamics are driven by innovation, regulatory compliance, and the ability to provide tailored solutions, positioning leading players for sustained growth in Japan’s evolving compounding pharmacy market.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In March 2024, Medios AG acquired Ceban Pharmaceuticals B.V., a Dutch leader in pharmaceutical compounding services operating across Belgium and Spain. This acquisition strengthened Medios’ specialty pharma platform and enhanced its position in Germany through improved cross-selling opportunities and supply chain efficiencies.
In November 2023, EQUASENS, in collaboration with ARZ Haan, acquired Apotheken Datenverarbeitung GmbH & Co. KG (ADV) and established PHARMAGEST Germany. This move expanded their digital pharmacy and IT service offerings, supporting compounding and dispensing operations in German pharmacies.
In August 2024, InterCure Ltd. extended its strategic partnership with Cookies to Germany, enabling the cultivation, manufacturing, and distribution of Cookies-branded medical cannabis products through licensed “Cookies Corners” within German pharmacies.
In March 2024, Medios AG acquired Ceban Pharmaceuticals B.V., boosting its Specialty Pharma platform and its positions in the Netherlands, Belgium, Spain, plus leveraging cross-selling and supply chain synergies in Germany.
Report Coverage
The research report offers an in-depth analysis based on Product Type, Pharmacy Type, Sterility, Therapeutic Area, Patient Demographics and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The Japan Compounding Pharmacies Market is expected to expand steadily, driven by rising demand for personalized medications.
Growth will be fueled by increasing prevalence of chronic diseases and rare conditions requiring patient-specific formulations.
Sterile compounding services are likely to witness significant adoption due to the rise in injectable and biologic therapies.
Pediatric and geriatric care will create new opportunities for customized dosage forms and alternative delivery methods.
Technological advancements in automation and precision compounding will enhance efficiency and product quality.
Regulatory support and streamlined compliance processes will encourage market expansion and innovation.
Collaboration between hospitals, clinics, and pharmacies will strengthen distribution networks and service reach.
Awareness among patients and caregivers about tailored therapies is expected to increase, boosting adoption rates.
Growth in specialty medications and hormone therapies will drive demand across targeted therapeutic areas.
Regional expansion beyond major metropolitan areas will support balanced market development across Japan.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: COMPOUNDING PHARMACIES MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Country-wise Price Trend
3.6.2 Price Trend by product CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Country-wise Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Country-wise Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Product Type & Pharmacy Type Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Country
6.1.1. Japan Compounding Pharmacies Market Import Revenue By Country
6.2. Export Analysis by Country
6.2.1. Japan Compounding Pharmacies Market Export Revenue By Country CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Japan Compounding Pharmacies Market: Company Market Share
7.2. Japan Compounding Pharmacies Market Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Country-wise Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: COMPOUNDING PHARMACIES MARKET – BY PRODUCT TYPE SEGMENT ANALYSIS
8.1. Compounding Pharmacies Market Overview by Product Type Segment
8.1.1. Compounding Pharmacies Market Revenue Share By Product Type
8.2. Oral Medications
8.3. Injectable Medications
8.4. Topical Preparations
8.5. Nasal Formulations
8.6. Others CHAPTER NO. 9: COMPOUNDING PHARMACIES MARKET – BY PHARMACY TYPE SEGMENT ANALYSIS
9.1. Compounding Pharmacies Market Overview by Pharmacy Type Segment
9.1.1. Compounding Pharmacies Market Revenue Share By Pharmacy Type
9.2. 503A Pharmacies
9.3. 503B Pharmacies CHAPTER NO. 10: COMPOUNDING PHARMACIES MARKET – BY STERILITY SEGMENT ANALYSIS
10.1. Compounding Pharmacies Market Overview by Sterility Segment
10.1.1. Compounding Pharmacies Market Revenue Share By Sterility
10.2. Sterile Compounding
10.3. Non-Sterile Compounding CHAPTER NO. 11: COMPOUNDING PHARMACIES MARKET – BY THERAPEUTIC AREA SEGMENT ANALYSIS
11.1. Compounding Pharmacies Market Overview by Therapeutic Area Segment
11.1.1. Compounding Pharmacies Market Revenue Share By Therapeutic Area
11.2. Hormone Replacement Therapy
11.3. Pain Management
11.4. Specialty Drugs
11.5. Dermatology
11.6. Nutritional Supplements
11.7. Others CHAPTER NO. 12: COMPOUNDING PHARMACIES MARKET – BY PATIENT DEMOGRAPHICS SEGMENT ANALYSIS
12.1. Compounding Pharmacies Market Overview by Patient Demographics Segment
12.1.1. Compounding Pharmacies Market Revenue Share By Patient Demographics
12.2. Adults
12.3. Pediatrics
12.4. Geriatrics
12.5. Others CHAPTER NO. 13: COMPOUNDING PHARMACIES MARKET – COUNTRY-WISE ANALYSIS
13.1. Compounding Pharmacies Market Overview by Country Segment
13.1.1. Japan Compounding Pharmacies Market Revenue Share By Country
13.1.2. Country
13.1.3. Japan Compounding Pharmacies Market Revenue By Country
13.1.4. Product Type
13.1.5. Japan Compounding Pharmacies Market Revenue By Product Type
13.1.6. Pharmacy Type
13.1.7. Japan Compounding Pharmacies Market Revenue By Pharmacy Type
13.1.8. Sterility
13.1.9. Japan Compounding Pharmacies Market Revenue By Sterility
13.1.10. Therapeutic Area
13.1.12. Japan Compounding Pharmacies Market Revenue By Therapeutic Area
13.1.13. Patient Demographics
13.1.14. Japan Compounding Pharmacies Market Revenue By Patient Demographics CHAPTER NO. 14: COMPANY PROFILES
14.1. Nichi-Iko Pharmaceutical Co. Ltd.
14.1.1. Company Overview
14.1.2. Product Portfolio
14.1.3. Financial Overview
14.1.4. Recent Developments
14.1.5. Growth Strategy
14.1.6. SWOT Analysis
14.2. Towa Pharmaceutical Co., Ltd.
14.3. Sato Pharmaceutical Co., Ltd.
14.4. Takeda Pharmaceutical Company Limited
14.5. Chugai Pharmaceutical Co., Ltd.
14.6. Daiichi Sankyo Company, Limited
14.7. Astellas Pharma Inc.
14.8. Eisai Co., Ltd.
14.9. Mochida Pharmaceutical Co., Ltd.
14.10. Otsuka Pharmaceutical Co., Ltd.
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for Japan Compounding Pharmacies Market, and what is its projected size in 2032?
The Japan Compounding Pharmacies Market was valued at USD 221.90 Million in 2024 and is projected to reach USD 403.45 Million by 2032.
At what Compound Annual Growth Rate is the Japan Compounding Pharmacies Market projected to grow between 2025 and 2032?
The Japan Compounding Pharmacies Market is expected to grow at a CAGR of 7.23% during the forecast period.
Which Japan Compounding Pharmacies Market segment held the largest share in 2024?
Oral medications held the largest share in 2024, accounting for 38% of the Japan Compounding Pharmacies Market.
What are the primary factors fueling the growth of the Japan Compounding Pharmacies Market?
Growth of the Japan Compounding Pharmacies Market is driven by rising demand for personalized medicine, chronic disease prevalence, and advancements in compounding technology.
Who are the leading companies in the Japan Compounding Pharmacies Market?
Key players in the Japan Compounding Pharmacies Market include Nichi-Iko Pharmaceutical, Towa Pharmaceutical, Sato Pharmaceutical, Takeda Pharmaceutical, and Daiichi Sankyo.
Which region commanded the largest share of the Japan Compounding Pharmacies Market in 2024?
The Kanto region held the largest share of the Japan Compounding Pharmacies Market in 2024 with 35%.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Germany Compounding Pharmacies Market size was valued at USD 381.95 Million in 2018, growing to USD 535.21 Million in 2024, and is anticipated to reach USD 829.32 Million by 2032, at a CAGR of 5.24% during the forecast period.
Italy Compounding Pharmacies Market size was valued at USD 267.42 Million in 2018, growing to USD 379.23 Million in 2024, and is anticipated to reach USD 597.97 Million by 2032, at a CAGR of 5.45% during the forecast period.
The Fondaparinux market size was valued at USD 686.65 million in 2024 and is anticipated to reach USD 1,107.44 million by 2032, growing at a CAGR of 6.3% during the forecast period.
U.S. Compounding Pharmacies market size was valued at USD 3,293.81 Million in 2018, rising to USD 4,743.43 Million in 2024, and is anticipated to reach USD 7,651.56 Million by 2032, growing at a CAGR of 5.73% during the forecast period.
The UK Compounding Pharmacies market was valued at USD 173.65 million in 2018 and grew to USD 237.16 million in 2024. The market is projected to reach USD 354.16 million by 2032, registering a CAGR of 4.79% during the forecast period.
The North America Compounding Pharmacies Market size was valued at USD 3,956.45 million in 2018 and increased to USD 5,674.29 million in 2024. It is anticipated to reach USD 9,265.27 million by 2032, registering a CAGR of 5.89% during the forecast period.
Dermatology Drugs Market size was valued USD 29.7 billion in 2024 and is anticipated to reach USD 63.2 billion by 2032, at a CAGR of 9.9% during the forecast period.
Australia Pharmaceutical Water Market size was valued at USD 389.54 million in 2018, grew to USD 779.59 million in 2024, and is anticipated to reach USD 1,736.49 million by 2032, expanding at a CAGR of 9.81% during the forecast period.
The Europe Pharmaceutical Water Market was valued at USD 4,290.41 million in 2018, grew to USD 7,235.40 million in 2024, and is anticipated to reach USD 14,105.75 million by 2032, expanding at a CAGR of 8.0% during the forecast period.
The North America Pharmaceutical Water Market was valued at USD 9,849.30 million in 2018, grew to USD 17,393.16 million in 2024, and is projected to reach USD 37,427.29 million by 2032, expanding at a CAGR of 9.4% during the forecast period.
Global Pharmaceutical Water Market size was valued at USD 23,162.04 million in 2018, grew to USD 41,343.44 million in 2024, and is anticipated to reach USD 88,711.39 million by 2032, expanding at a CAGR of 9.33% during the forecast period.
Japan Pharmaceutical Water Market size was valued at USD 819.04 million in 2018, grew to USD 1,672.74 million in 2024, and is anticipated to reach USD 3,843.83 million by 2032, expanding at a CAGR of 10.21% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$2999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
